NCT06514794View on ClinicalTrials.gov

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

PHASE2RecruitingINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2028

Conditions
T-cell Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma
Interventions
BIOLOGICAL

WU-CART-007

A single IV infusion of WU-CART-007

Trial Locations (7)

3000

RECRUITING

Peter Mac Callum Cancer Institute, Melbourne

RECRUITING

Royal Children's Melbourne, Melbourne

19390

RECRUITING

Children's Hospital of Philadelphia, Philadelphia

63108

RECRUITING

Washington University Saint Louis, St Louis

77030

RECRUITING

MD Anderson Cancer Center, Houston

90027

RECRUITING

Children's Hospital Los Angeles, Los Angeles

91010

RECRUITING

City of Hope, Duarte

All Listed Sponsors
lead

Wugen, Inc.

INDUSTRY